ProCE Banner Activity

Rethinking Cytokine Therapy in the Management of Advanced Melanoma

Clinical Thought
In this commentary, an expert explains how high-dose IL-2 continues to have a role in the management of resistant or progressive melanoma and discusses evolving ways to incorporate IL-2 therapy into melanoma care.

Released: February 15, 2021

Expiration: February 14, 2022

Share

Faculty

Elizabeth Buchbinder

Elizabeth Buchbinder, MD

Assistant Professor
Department of Medical Oncology
Dana-Farber Cancer Institute
Physician
Melanoma Disease Center
Medical Oncology
Boston, Massachusetts

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by an educational grant from

Clinigen Inc

Faculty Disclosure

Primary Author

Elizabeth Buchbinder, MD

Assistant Professor
Department of Medical Oncology
Dana-Farber Cancer Institute
Physician
Melanoma Disease Center
Medical Oncology
Boston, Massachusetts

Elizabeth Buchbinder, MD, has disclosed that she has received consulting fees from Apexigen, Bristol-Myers Squibb, Novartis, and Shionogi.